散发性早发性弥漫型胃癌体细胞CDH1改变频率高,而体细胞RHOA突变频率低于晚发性胃癌
该研究对109例韩国早发性弥漫型胃癌(DGC)样本进行外显子组、RNA测序、SNP6.0芯片和靶向测序,并与115例晚发性DGC比较。早发性DGC中CDH1和TGFBR1突变比例高于晚发性,RHOA突变比例低于晚发性;CDH1改变与更短生存时间相关(HR 3.4,95%CI 1.5-7.7),而RHOA突变无此关联。
要点
- 早发性DGC中CDH1突变占42.2%,高于晚发性DGC的17.4%(P<.001)。
- 早发性DGC中RHOA突变占9.2%,低于晚发性DGC的19.1%(P=.033)。
- CDH1改变与早发性DGC患者更短生存相关(HR 3.4,95%CI 1.5-7.7),RHOA突变无此关联。
核心结论
- 早发性DGC中CDH1或TGFBR1体细胞突变比例高于晚发性DGC,而RHOA体细胞突变比例低于晚发性DGC。
- CDH1改变而非RHOA突变与患者更短生存时间相关,可能解释早发性胃癌的侵袭性临床过程。
- 早发性胃癌的女性优势可能与该人群中较高的体细胞CDH1和TGFBR1突变率相关。
研究设计与样本
- 对韩国109例早发性DGC样本(54.1%女性,中位年龄38岁)进行全外显子组测序、RNA测序、SNP6.0芯片和靶向测序分析。
- 与韩国115例晚发性DGC对照(29.6%女性,中位年龄67岁)的SNP6.0芯片和靶向测序数据比较。
- 排除携带CDH1、TP53和ATM致病性胚系突变的患者,聚焦体细胞改变。
- 使用MutSig2CV评估突变基因的显著性,并在DGC细胞中用siRNA沉默RHOA或CDH1进行细胞实验。
主要发现
- 早发性DGC中显著突变基因包括CDH1、TP53、ARID1A、KRAS、PIK3CA、ERBB3、TGFBR1、FBXW7、RHOA和MAP2K1。
- 109例早发性DGC均无致病性胚系CDH1突变。
- 早发性DGC中CDH1突变占42.2%,高于晚发性DGC的17.4%(P<.001);TGFBR1突变占7.3%,高于晚发性DGC的0.9%(P=.014)。
- 早发性DGC中RHOA突变占9.2%,低于晚发性DGC的19.1%(P=.033)。
- 早发性DGC女性患者CDH1或TGFBR1突变显著多于男性患者;CDH1改变与更短生存相关(HR 3.4,95%CI 1.5-7.7),RHOA突变无此关联。
临床怎么用
- 作者认为CDH1改变而非RHOA突变与早发性DGC患者更短生存时间相关,可能解释该病的侵袭性临床过程。
- 作者认为早发性胃癌的女性优势可能与该人群中较高的体细胞CDH1和TGFBR1突变率相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Early-onset gastric cancer, which develops in patients younger than most gastric cancers, is usually detected at advanced stages, has diffuse histologic features, and occurs more frequently in women. We investigated somatic genomic alterations associated with the unique characteristics of sporadic diffuse gastric cancers (DGCs) from younger patients. METHODS: We conducted whole exome and RNA sequence analyses of 80 resected DGC samples from patients 45 years old or younger in Korea. Patients with pathogenic germline mutations in CDH1, TP53, and ATM were excluded from the onset of this analysis, given our focus on somatic alterations. We used MutSig2CV to evaluate the significance of mutated genes. We recruited 29 additional early-onset Korean DGC samples and performed SNP6.0 array and targeted sequencing analyses of these 109 early-onset DGC samples (54.1% female, median age, 38 years). We compared the SNP6.0 array and targeted sequencing data of the 109 early-onset DGC samples with those from diffuse-type stomach tumor samples collected from 115 patients in Korea who were 46 years or older (late onset) at the time of diagnosis (controls; 29.6% female, median age, 67 years). We compared patient survival times among tumors from different subgroups and with different somatic mutations. We performed gene silencing of RHOA or CDH1 in DGC cells with small interfering RNAs for cell-based assays. RESULTS: We identified somatic mutations in the following genes in a significant number of early-onset DGCs: the cadherin 1 gene (CDH1), TP53, ARID1A, KRAS, PIK3CA, ERBB3, TGFBR1, FBXW7, RHOA, and MAP2K1. None of 109 early-onset DGC cases had pathogenic germline CDH1 mutations. A higher proportion of early-onset DGCs had mutations in CDH1 (42.2%) or TGFBR1 (7.3%) compared with control DGCs (17.4% and 0.9%, respectively) (P < .001 and P = .014 for CDH1 and TGFBR1, respectively). In contrast, a smaller proportion of early-onset DGCs contained mutations in RHOA (9.2%) than control DGCs (19.1%) (P = .033). Late-onset DGCs in The Cancer Genome Atlas also contained less frequent mutations in CDH1 and TGFBR1 and more frequent RHOA mutations, compared with early-onset DGCs. Early-onset DGCs from women contained significantly more mutations in CDH1 or TGFBR1 than early-onset DGCs from men. CDH1 alterations, but not RHOA mutations, were associated with shorter survival times in patients with early-onset DGCs (hazard ratio, 3.4; 95% confidence interval, 1.5-7.7). RHOA activity was reduced by an R5W substitution-the RHOA mutation most frequently detected in early-onset DGCs. Silencing of CDH1, but not RHOA, increased migratory activity of DGC cells. CONCLUSIONS: In an integrative genomic analysis, we found higher proportions of early-onset DGCs to contain somatic mutations in CDH1 or TGFBR1 compared with late-onset DGCs. However, a smaller proportion of early-onset DGCs contained somatic mutations in RHOA than late-onset DGCs. CDH1 alterations, but not RHOA mutations, were associated with shorter survival times of patients, which might account for the aggressive clinical course of early-onset gastric cancer. Female predominance in early-onset gastric cancer may be related to relatively high rates of somatic CDH1 and TGFBR1 mutations in this population.
引用
- Cho SY, Park JW, Liu Y, et al. Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers. Gastroenterology. 2017. PMID: 28522256. doi:10.1053/j.gastro.2017.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。